Electronegative LDL and lipid abnormalities in patients undergoing hemodialysis and peritoneal dialysis

被引:24
|
作者
Lobo, J. [2 ]
Santos, F. [1 ]
Grosso, D. [2 ]
Lima, R. [1 ,4 ]
Barreira, A. L. [1 ,4 ]
Leite, M. [1 ,4 ]
Mafra, D. [3 ]
Abdalla, S. P. [2 ]
机构
[1] Univ Fed Rio de Janeiro, Div Nephrol, BR-24220301 Rio De Janeiro, Brazil
[2] Univ Sao Paulo, Sch Pharmaceut Sci, Sao Paulo, Brazil
[3] Univ Fed Fluminense, Dept Clin Nutr, Rio De Janeiro, Brazil
[4] Univ Fed Fluminense, Ctr Integrado Nefrol, Rio De Janeiro, Brazil
来源
NEPHRON CLINICAL PRACTICE | 2008年 / 108卷 / 04期
关键词
hemodialysis; peritoneal dialysis; electronegative low-density lipoprotein; cardiovascular disease;
D O I
10.1159/000127982
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Oxidative modification of low-density lipoprotein (LDL) has been demonstrated in patients with end-stage renal disease, where it is associated with oxidative stress and plays a key role in the pathogenesis of atherosclerosis. In this context, the generation of minimally oxidized LDL, also called electronegative LDL [ LDL(-)], has been associated with active disease, and is a detectable sign of atherogenic tendencies. The purpose of this study was to evaluate serum LDL(-) levels and anti-LDL(-)IgG autoantibodies in end-stage renal disease patients on dialysis, comparing patients on hemodialysis (HD), peritoneal dialysis (PD) and a control group. In addition, the serum lipid profile, nutritional status, biochemical data and parameters of mineral metabolism were also evaluated. Methods: The serum levels of LDL(-) and anti-LDL(-) IgG autoantibodies were measured in 25 patients undergoing HD and 11 patients undergoing PD at the Centro Integradode Nefrologia, Rio de Janeiro, Brazil. Ten healthy subjects served as a control group. Serum levels of albumin, total cholesterol, triglycerides and lipoproteins were measured. Calculations of subjects' body mass index and measurements of waist circumference, triceps skin fold and arm muscle area were performed. Measurements of hematocrit, serum blood urea nitrogen, creatinine, parathyroid hormone, phosphorus and calcium were taken. Results: Levels of LDL(-) were higher in HD patients (575.6 +/- 233.1 mu g/ml) as compared to PD patients (223.4 +/- 117.5 mu g/ml, p < 0.05), which in turn were higher than in the control group (54.9 +/- 33.3 mu g/ml, p < 0.01). The anti-LDL(-) IgG autoantibodies were increased in controls (0.36 +/- 0.09 mu g/ ml) as compared to PD (0.28 +/- 0.12 mu g/ml, p < 0.001) and HD patients (0.2 +/- 0.1 mu g/ml, p < 0.001). The mean values of total cholesterol and LDL were considered high in the PD group, whereas the mean triceps skin fold was significantly lower in the HD group. Conclusion: Levels of LDL(-) are higher in renal patients on dialysis than in normal individuals, and are reciprocally related to IgG autoantibodies. LDL(-) may be a useful marker of oxidative stress, and this study suggests that HD patients are more susceptible to cardiovascular risk due to this condition. Moreover, autoantibodies reactive to LDL(-) may have protective effects in chronic kidney disease. Copyright (C) 2008 S. Karger AG, Basel.
引用
收藏
页码:C298 / C304
页数:7
相关论文
共 50 条
  • [41] Hyperleptinemia in uremic patients undergoing conservative management, peritoneal dialysis, and hemodialysis:: A comparative analysis
    Fontán, MP
    Rodríguez-Carmona, A
    Cordido, F
    García-Buela, J
    AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 34 (05) : 824 - 831
  • [42] Vildagliptin is Effective for Glycemic Control in Diabetic Patients Undergoing either Hemodialysis or Peritoneal Dialysis
    Hiroyuki Ito
    Mizuo Mifune
    Eriko Matsuyama
    Masahide Furusho
    Takashi Omoto
    Masahiro Shinozaki
    Shinya Nishio
    Shinichi Antoku
    Mariko Abe
    Michiko Togane
    Shoji Koga
    Tsutomu Sanaka
    Diabetes Therapy, 2013, 4 : 321 - 329
  • [43] Vildagliptin is Effective for Glycemic Control in Diabetic Patients Undergoing either Hemodialysis or Peritoneal Dialysis
    Ito, Hiroyuki
    Mifune, Mizuo
    Matsuyama, Eriko
    Furusho, Masahide
    Omoto, Takashi
    Shinozaki, Masahiro
    Nishio, Shinya
    Antoku, Shinichi
    Abe, Mariko
    Togane, Michiko
    Koga, Shoji
    Sanaka, Tsutmou
    DIABETES THERAPY, 2013, 4 (02) : 321 - 329
  • [44] Infections in patients undergoing peritoneal dialysis
    Vas, S
    Oreopoulos, DG
    INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2001, 15 (03) : 743 - +
  • [45] Hypoglycemic therapy in patients on hemodialysis and peritoneal dialysis
    Bondar', I. A.
    Klimontov, V. V.
    DIABETES MELLITUS, 2010, 13 (04): : 87 - 92
  • [46] Thromboelastpgraphic changes in hemodialysis and peritoneal dialysis patients
    Kuperman, A.
    Braester, A.
    Hassan, K.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 701 - 701
  • [47] Trace metals in peritoneal dialysis patients and hemodialysis patients
    Burgess, E
    Audette, R
    Hons, R
    Taub, K
    Schorr, S
    Mandin, H
    TRACE ELEMENTS IN MAN AND ANIMALS - 9, 1997, : 132 - 133
  • [48] PERITONEAL DIALYSIS AND HEMODIALYSIS
    DUNEA, G
    MEDICAL CLINICS OF NORTH AMERICA, 1971, 55 (01) : 155 - &
  • [49] PHARMACOKINETICS OF TOBRAMYCIN IN PATIENTS WITH STABLE RENAL IMPAIRMENT, PATIENTS UNDERGOING PERITONEAL-DIALYSIS, AND PATIENTS ON CHRONIC HEMODIALYSIS
    JAFFE, G
    MEYERS, BR
    HIRSCHMAN, SZ
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1974, 5 (06) : 611 - 616
  • [50] Sleep disorders in patients with end-stage renal disease undergoing dialysis: comparison between hemodialysis, continuous ambulatory peritoneal dialysis and automated peritoneal dialysis
    Ricardo L. M. Losso
    Gisele R. Minhoto
    Miguel C. Riella
    International Urology and Nephrology, 2015, 47 : 369 - 375